{"database": "lobbying", "table": "lobbying_activities", "rows": [[2661773, "a62220e9-e6f9-4d4d-a619-559a6611d894", "Q2", "SWISHER INTERNATIONAL, INC., F/K/A SI GROUP CLIENT SERVICES", 401105162, "SWISHER INTERNATIONAL, INC., F/K/A SI GROUP CLIENT SERVICES", 2021, "second_quarter", "TOB", "Outreach and monitoring related to the tobacco industry.\nCongressional outreach and monitoring related to federal excise taxes, including:\n-H.R. 3407 / S. 411, MOMMA's Act.\n-H.R. 2786 / S. 1314, Tobacco Tax Equity Act.\nCongressional outreach and monitoring related to Congressional priorities on tobacco products and flavorings.\nCongressional outreach and monitoring related to H.R. 4356 /Senate draft, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, FY2022.\nOutreach and monitoring related to federal COVID-19 relief and stimulus legislation including:\n-H.R. 1319, American Rescue Plan Act of 2021.\n\nMonitored the following:\n-FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees.\n-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).\n-Federal and legislative action related to the marketing and advertising of tobacco products.\n-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.\n-FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28) \n-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)\n-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)\n-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)\n-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)\n-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", null, 360000, 0, 0, "2021-07-20T14:55:51.713000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2661773"], "units": {}, "query_ms": 0.375034986063838, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}